MAY 14, 2020 3:00 PM CEST

Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    Biography

      Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.


    Abstract

    Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfDNA next generation sequencing (NGS) testing is usually low. This phenomenon might be due to different factors, including sequencing artifacts, clonal hematopoiesis and/or tumor heterogeneity. Therefore, appropriate internal and external validation of NGS methods are required before their use in the clinical scenario. Nevertheless, cfDNA testing can provide information that is complementary to tissue testing and that can aid to personalize treatments in patients with metastatic tumors. In addition, cfDNA testing might allow monitoring response to treatments and identifying mechanisms of acquired resistance that offer opportunity for therapeutic intervention. Results of liquid biopsy testing with NGS should be discussed in the Molecular Tumor Board to guarantee their appropriate interpretation and integration in the clinical scenario.

     

    Learning Objectives:

    1. Acquire knowledge on the limits and potential of cfDNA testing in solid tumors

    2. Understand how to use cfDNA testing in clinical research


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    Loading Comments...
    Show Resources
    Attendees
    • See more